Arvind Mathur - Concepedia

Author

Arvind Mathur

Bristol-Myers Squibb (United States)ORCID

Also Known As

A. MATHUR, A. Mathur, ARVIND MATHUR, Arnab Dutta, Arvind Mathur, Gupta, Anuradha, K. Toth, Mathur, A., Mathur, Arvind

266

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Biocon (India)Bristol-Myers Squibb (India)Bristol-Myers Squibb (Germany)Syngene International (India)

About

Arvind Mathur is an author at Bristol-Myers Squibb (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	41	1.2K
2	Natural Sciences	21	31	1K
3	Biochemistry	19	28	918
4	Biomolecular Engineering	10	10	372
5	Engineering	5	5	288

Arvind Mathur

Publications

Citations

H-Index

Page 1

	Year	Citations
Synthesis of Cyclobutane-Fused Tetracyclic Scaffolds via Visible-Light Photocatalysis for Building Molecular Complexity Martins S. Oderinde, Edna Mao, Antonio Ramı́rez, Journal of the American Chemical Society	2020	144
Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers Scott H. Watterson, George V. De Lucca, Qing Shi, Journal of Medicinal Chemistry	2016	142
Discovery and Preclinical Studies of (<i>R</i>)-1-(4-(4-Fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5- methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor Rajeev S. Bhide, Zhen‐Wei Cai, Yong‐Zheng Zhang, Journal of Medicinal Chemistry	2006	131
Utilization of C(<i>sp</i><sup>3</sup>)‐Carboxylic Acids and Their Redox‐Active Esters in Decarboxylative Carbon−Carbon Bond Formation Sukhen Karmakar, Arundutt Silamkoti, Nicholas A. Meanwell, Advanced Synthesis & Catalysis Synthetic StrategyNovel OrganocatalystsEngineeringMacromolecular EngineeringCross-coupling Reaction	2021	131
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK) Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Journal of Medicinal Chemistry Tyrosine KinaseImmunologyQuantitative PharmacologyBiological TherapyInnate Immunity	2019	104
Discovery of a 2,4-Disubstituted Pyrrolo[1,2-<i>f</i>][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development Mark D. Wittman, Joan M. Carboni, Yang Zheng, Journal of Medicinal Chemistry	2009	94
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte, Journal of Medicinal Chemistry	2021	93
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors Ashvinikumar V. Gavai, Claude Quesnelle, Derek Norris, ACS Medicinal Chemistry Letters Solid TumorsPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2015	88
Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity Martins S. Oderinde, Antonio Ramı́rez, T. G. Murali Dhar, The Journal of Organic Chemistry Combinatorial ChemistryEngineeringSynthetic PhotochemistryOrganic ChemistryChemistry	2020	78
Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors James Sutton, Scott A. Bolton, Malcolm E. Davis, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistrySolid-phase SynthesisMedicinePharmacotherapyDrug Development	2004	63

Page 1